Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Alessandra De Paula Pohl"'
Autor:
Ashley D. Hadjis, Natalia S. Nunes, Shanzay M. Khan, Rochelle E. Fletcher, Alessandra de Paula Pohl, David J. Venzon, Michael A. Eckhaus, Christopher G. Kanakry
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://doaj.org/article/2353e45dfe2c40c589b13c56dc2a4754
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Anti-drug antibody formation poses tremendous obstacles for optimal treatment of hemophilia A (HA). In this study, we sought to utilize chimeric receptor-modified natural regulatory T cells (Tregs) to target FVIII-specific memory B cells, which are r
Externí odkaz:
https://doaj.org/article/ba679ffdabd349ac97202bb5f125110c
Autor:
Rochelle E. Fletcher, Natalia S. Nunes, Michael T. Patterson, Natasha Vinod, Shanzay M. Khan, Suresh K. Mendu, Xianghong Li, Alessandra de Paula Pohl, Lucas P. Wachsmuth, Hyoyoung Choo-Wosoba, Michael A. Eckhaus, David J. Venzon, Christopher G. Kanakry
Publikováno v:
Blood Adv
Posttransplantation cyclophosphamide (PTCy), given on days +3 and +4, reduces graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT), but its immunologic underpinnings are not fully understood. In a T-cell–replet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f209404a429cedb4583d3435bde76cfb
https://doi.org/10.1182/bloodadvances.2022007026
https://doi.org/10.1182/bloodadvances.2022007026
Autor:
Michael T. Patterson, Shanzay M. Khan, Natalia S. Nunes, Rochelle E. Fletcher, Jing Bian, Ashley D. Hadjis, Michael A. Eckhaus, Suresh K. Mendu, Alessandra de Paula Pohl, David J. Venzon, Hyoyoung Choo-Wosoba, Kazusa Ishii, Haiying Qin, Terry J. Fry, Maggie Cam, Christopher G. Kanakry
Publikováno v:
Blood. 141:659-672
Relapse limits the therapeutic efficacy both of chimeric antigen receptor (CAR) T cells and allogeneic hematopoietic cell transplantation (allo-HCT). Patients may undergo these therapies sequentially to prevent or treat relapsed malignancy. However,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c01008114de1005258e673a76ca91af4
https://doi.org/10.1182/blood.2022016660
https://doi.org/10.1182/blood.2022016660
Autor:
Ashley D, Hadjis, Natalia S, Nunes, Shanzay M, Khan, Rochelle E, Fletcher, Alessandra de Paula, Pohl, David J, Venzon, Michael A, Eckhaus, Christopher G, Kanakry
Publikováno v:
Frontiers in immunology. 13
Post-transplantation cyclophosphamide (PTCy) reduces the incidence and severity of graft-versus-host disease (GVHD), thereby improving the safety and accessibility of allogeneic hematopoietic cell transplantation (HCT). We have shown that PTCy works
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::100d2d4404b8c32346ecce6dd1e82297
https://pubmed.ncbi.nlm.nih.gov/35493453
https://pubmed.ncbi.nlm.nih.gov/35493453
Autor:
Alessandra De Paula Pohl, Tania Maldonado, Christoph Königs, Ai-Hong Zhang, Anja Schmidt, David W. Scott
Publikováno v:
Cellular immunology. 358
The expansion of polyclonal T regulatory cells (Tregs) offers great promise for the treatment of immune-mediated diseases, such as multiple sclerosis (MS). However, polyclonal Tregs can be non-specifically immunosuppressive. Based on the advancements
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0a1906a8635d3e2ba419b4825b452f5
https://pubmed.ncbi.nlm.nih.gov/33053469
https://pubmed.ncbi.nlm.nih.gov/33053469